These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25711321)

  • 1. Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Sharma S; Babiker AG; Emery S; Gordin FM; Lundgren JD; Neaton JN; Bakowska E; Schechter M; Wiselka MJ; Wolff MJ;
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):30-6. PubMed ID: 25711321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Law MG; Achhra A; Deeks SG; Gazzard B; Migueles SA; Novak RM; Ristola M;
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):37-45. PubMed ID: 25711322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Geffen N; Aagaard P; Corbelli GM; Meulbroek M; Peavy D; Rappoport C; Schwarze S; Collins S;
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):10-3. PubMed ID: 25711318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
    Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE;
    Lancet Respir Med; 2016 Dec; 4(12):980-989. PubMed ID: 27773665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.
    Molina JM; Grund B; Gordin F; Williams I; Schechter M; Losso M; Law M; Ekong E; Mwelase N; Skoutelis A; Wiselka MJ; Vandekerckhove L; Benfield T; Munroe D; Lundgren JD; Neaton JD;
    Lancet HIV; 2018 Apr; 5(4):e172-e180. PubMed ID: 29352723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
    Kunisaki KM; Niewoehner DE; Collins G; Nixon DE; Tedaldi E; Akolo C; Kityo C; Klinker H; La Rosa A; Connett JE;
    HIV Med; 2015 Apr; 16 Suppl 1(0 0):119-28. PubMed ID: 25711330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.
    Helleberg M; Kronborg G; Larsen CS; Pedersen G; Pedersen C; Obel N; Gerstoft J
    HIV Med; 2013 Jul; 14(6):362-9. PubMed ID: 23433434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.
    Babiker AG; Emery S; Fätkenheuer G; Gordin FM; Grund B; Lundgren JD; Neaton JD; Pett SL; Phillips A; Touloumi G; Vjechaj MJ;
    Clin Trials; 2013; 10(1 Suppl):S5-S36. PubMed ID: 22547421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4 count recovery and associated factors among individuals enrolled in the South African antiretroviral therapy programme: An analysis of national laboratory based data.
    Kufa T; Shubber Z; MacLeod W; Takuva S; Carmona S; Bor J; Gorgens M; Pillay Y; Puren A; Eaton JW; Fraser-Hurt N
    PLoS One; 2019; 14(5):e0217742. PubMed ID: 31150489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection.
    Sharma S; Schlusser KE; de la Torre P; Tambussi G; Draenert R; Pinto AN; Metcalf JA; Neaton JD; Laeyendecker O;
    AIDS; 2019 Jul; 33(8):1335-1344. PubMed ID: 31157663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection.
    Lifson AR; Grund B; Gardner EM; Kaplan R; Denning E; Engen N; Carey CL; Chen F; Dao S; Florence E; Sanz J; Emery S;
    AIDS; 2017 Apr; 31(7):953-963. PubMed ID: 28121710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy.
    Jose S; Quinn K; Hill T; Leen C; Walsh J; Hay P; Fisher M; Post F; Nelson M; Gompels M; Johnson M; Chadwick D; Gilson R; Sabin C; Fidler S;
    AIDS; 2014 Jun; 28(9):1333-9. PubMed ID: 24583670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.
    Bouteloup V; Sabin C; Mocroft A; Gras L; Pantazis N; Le Moing V; d'Arminio Monforte A; Mary-Krause M; Roca B; Miro JM; Battegay M; Brockmeyer N; Berenguer J; Morlat P; Obel N; De Wit S; Fätkenheuer G; Zangerle R; Ghosn J; Pérez-Hoyos S; Campbell M; Prins M; Chêne G; Meyer L; Dorrucci M; Torti C; Thiébaut R;
    HIV Med; 2017 Jan; 18(1):33-44. PubMed ID: 27625009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The per-protocol effect of immediate versus deferred antiretroviral therapy initiation.
    Lodi S; Sharma S; Lundgren JD; Phillips AN; Cole SR; Logan R; Agan BK; Babiker A; Klinker H; Chu H; Law M; Neaton JD; Hernán MA;
    AIDS; 2016 Nov; 30(17):2659-2663. PubMed ID: 27782964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004-18: a cohort study.
    Lee JS; Humes E; Hogan BC; Justice AC; Klein M; Gebo K; John Gill M; Silverberg MJ; Rebeiro P; Horberg M; Karris M; Rabkin C; Moore RD; Althoff KN;
    Lancet HIV; 2022 Mar; 9 Suppl 1():S2. PubMed ID: 35304844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
    Lodi S; Phillips A; Logan R; Olson A; Costagliola D; Abgrall S; van Sighem A; Reiss P; Miró JM; Ferrer E; Justice A; Gandhi N; Bucher HC; Furrer H; Moreno S; Monge S; Touloumi G; Pantazis N; Sterne J; Young JG; Meyer L; Seng R; Dabis F; Vandehende MA; Pérez-Hoyos S; Jarrín I; Jose S; Sabin C; Hernán MA;
    Lancet HIV; 2015 Aug; 2(8):e335-43. PubMed ID: 26423376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa.
    Bock P; Nel K; Fatti G; Sloot R; Ford N; Voget J; Gunst C; Grobbelaar N; Louis F; Floyd S; Hayes R; Ayles H; Beyers N; Fidler S;
    HIV Med; 2019 Jul; 20(6):392-403. PubMed ID: 30963667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.
    Nakanjako D; Kiragga AN; Musick BS; Yiannoutsos CT; Wools-Kaloustian K; Diero L; Oyaro P; Lugina E; Ssali JC; Kambugu A; Easterbrook P
    AIDS; 2016 Jul; 30(12):1913-22. PubMed ID: 26959510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
    ; Lundgren J; Babiker A; Gordin F; Emery S; Fätkenheuer G; Molina JM; Wood R; Neaton JD
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):1-9. PubMed ID: 25711317
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study.
    Katz IT; Kaplan R; Fitzmaurice G; Leone D; Bangsberg DR; Bekker LG; Orrell C
    PLoS Med; 2017 Nov; 14(11):e1002434. PubMed ID: 29136014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.